Find information on thousands of medical conditions and prescription drugs.

Cardiolite

Cardiolite® is the brand name of sestamibi, a radiopharmaceutical used in nuclear medicine imaging. It is also known as methoxyisobutylisonitrile or MIBI. The radioisotope attached to the sestamibi molecule is technetium-99m, forming ⁹⁹Tc^m-sestamibi (or Tc99m MIBI). more...

Home

Caduet

Calan

Campath

Capoten

Cardura

Casodex

Cathine

Ceclor

Cefotan

Cefzil

Celexa

Cerebyx

Chenodeoxycholic acid

Cholac

Choriogonadotropin alfa

Chorionic gonadotropin

Cialis

Cipro

Climara

Clomid

Colyte

Commit

Coreg

Corgard

Cotrim

Cozaar

Crestor

Cylert

Cytotec

Its main use is for imaging the myocardium (heart muscle). It is also used for imaging hyperparathyroidism of the parathyroid glands and for radioguided surgery of the parathyroid.

Cardiac imaging

When injected intravenously into a patient, it concentrates in the myocardium dependent on the myocardial blood flow. Single photon emission computed tomography (SPECT) imaging of the heart is performed using a gamma camera to detect the gamma rays emitted by the technetium-99m as it decays. Two sets of images are acquired. For one set, the patient is stressed either by exercising on a treadmill or by using a drug. The Tc99m MIBI is injected at peak stress and then imaging is performed. In the second set the Tc99m MIBI is injected whilst the patient is at rest and then imaged. The resulting two sets of images can be compared to distinguish ischaemic from infarcted areas of the myocardium. The imaging is also known as myocardial perfusion imaging (MPI).

Parathyroid imaging

In hyperparathyroidism, one or more of the four parathyroid glands have developed a benign tumour called an adenoma. The affected gland takes up Tc99m MIBI following an intravenous injection. The patient's neck is imaged with a gamma camera to show the tumour.

Radioguided surgery of the parathyroids

Following the administration of Tc99m MIBI it collects in overactive parathyroid glands. During surgery, the surgeon can use a probe sensitive to gamma rays to locate the overactive parathyroid before removing it.

Read more at Wikipedia.org

• [List your site here Free!]

Syncor International to Hold Conference Call to Discuss Its Recent Press Release Regarding Cardiolite Distribution Agreement
From Business Wire, 6/20/01

Business Editors

WOODLAND HILLS, Calif.--(BUSINESS WIRE)--June 20, 2001

Syncor International Corp. (Nasdaq:SCOR) will hold a conference call on Thursday, June 21, 2001, at 10:30 a.m. (Eastern time) to discuss its recent press release on the Cardiolite(R) Distribution Agreement.

To access the call, dial 800/949-2165 approximately 10 minutes before the start of the call (access code -- "Syncor"). The investor conference call will also be simulcast on Syncor's Web site: www.syncor.com.

A replay of the call will be available until 11 p.m. (PST) on July 13, 2001. To access the replay, dial 800/839-6713 (access code 4310274). A replay will also be available on Syncor's Web site -- www.syncor.com. The Web site replay will also be available until July 13, 2001.

Syncor is a leading provider of high-technology health-care services concentrating on nuclear pharmacy services, medical imaging, niche manufacturing and radiotherapy. In the nuclear pharmacy services business, Syncor compounds and dispenses radiopharmaceuticals for diagnostic and therapeutic use by nuclear medicine departments in hospitals and outpatient clinics.

Syncor distributes these time-critical pharmaceuticals through an integrated network of 130 domestic and 19 international nuclear pharmacies.

Syncor also offers information management services; the company currently provides these services to more than 7,000 U.S.-based customers.

Medical imaging services are provided through an integrated network of 62 domestic and 13 international owned or operated facilities (including two catheterization laboratories overseas). Domestic medical imaging operations are conducted by Syncor's wholly owned subsidiary, Comprehensive Medical Imaging Inc., and international operations are conducted by Syncor Overseas Ltd.

Syncor also owns or operates three domestic and two international production facilities for positron emission tomography (PET) radiopharmaceuticals, and is a party to a series of agreements to make PET technology more accessible to health-care providers and patients nationwide. Syncor also produces and markets Iodine-125 brachytherapy seeds used to treat prostate cancer, and operates a gamma knife facility in South America.

News on Demand: 800/546-8172

Web Site: www.syncor.com

Return to Cardiolite

Home

Contact

Resources

Exchange Links

ebay